Results 61 to 70 of about 5,304 (170)
Supplementary Figure S1: Acalabrutinib is a more potent BCR-inhibitor than ibrutinib in vivo at 1mg/kg and 3mg/kg. Supplementary Figure S2: In vivo gating strategy for murine cells.
Carsten U. Niemann (14998799) +19 more
core +1 more source
Aim: Real-world evidence comparing healthcare resource utilization (HRU) and costs between ibrutinib and acalabrutinib, two Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL ...
Kerry A Rogers +9 more
doaj +1 more source
Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma [PDF]
Zanubrutinib and acalabrutinib have demonstrated efficacy in separate single-arm clinical trials in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL).
Shah, B. +9 more
core +1 more source
Supplementary Data from Circulating Tumor DNA–Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and ...
Jonathan Weiss (254022) +15 more
core +1 more source
International audienceAcalabr utinib, a second-generation Br uton's tyrosine kinase inhibitor (BTKi), offers an improved safety profile compared to first-generation inhibitors like ibrutinib.
Ederhy, Stéphane +7 more
core +1 more source
Comparison of BTK/acalabrutinib and BTK/tirabrutinib complexes.
a. Superposition of the BTK KD/tirabrutinib structure solved here with the previously solved structure (PDB code: 5P9M) showing the different activation loop conformations as in Fig 2c. b.
Amy H. Andreotti (366314) +1 more
core +1 more source
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source
Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives
Acalabrutinib, a second-generation Bruton's tyrosine kinase inhibitor (BTKi), is characterized by enhanced specificity and selectivity for BTK with minimal off-target effects, offering a significant evolution in the treatment of chronic lymphocytic ...
Danesi, Romano, Gaidano, Gianluca
core +1 more source
Ibrutinib and acalabrutinib are first- and next-generation Bruton Tyrosine Kinase inhibitors (BTKi), respectively, approved for chronic lymphocytic leukemia (CLL).
Raúl Córdoba +7 more
doaj +1 more source
Thermodynamic characterisation of covalent ligand binding
Background and Purpose Differential scanning fluorimetry (DSF) is a common and straightforward method to evaluate the thermal stability of proteins and has been heavily used for ligand binding characterisation as well as for screening. One class of compounds that is less typically evaluated by DSF are covalent binders.
Rebecca Hertzman +4 more
wiley +1 more source

